KCNQ2 encephalopathy is a genetic epileptic encephalopathy caused by pathogenic variants in the KCNQ2 gene, which encodes the Kv7.2 potassium channel subunit. Unlike Dravet syndrome (SCN1A) which is uniformly loss-of-function, KCNQ2 variants can cause either loss-of-function (LOF) or gain-of-function (GOF), creating unique challenges for gene therapy development. Currently, no clinical-stage gene therapy programs exist for KCNQ2, but academic groups at Children's Hospital of Philadelphia (CHOP) and UC Davis are actively advancing preclinical programs.
| Parameter |
Value |
| Indication |
KCNQ2 encephalopathy (KCNQ2-E) |
| Gene |
KCNQ2 (Kv7.2 potassium channel) |
| Modality |
AAV gene therapy |
| Development Stage |
Preclinical / Research |
| Delivery Route |
To be determined (ICV, ICM, or IV with BBB-crossing capsid) |
| Target Population |
Pediatric patients (infancy to childhood) |
KCNQ2 encephalopathy (also known as KCNQ2-E) is a severe neurodevelopmental disorder characterized by:
- Onset: Early infancy (first week to months of life), often within the neonatal period
- Seizure types: Focal seizures, tonic seizures, epileptic spasms, often multifocal
- EEG patterns: Burst-suppression pattern is common in the neonatal period
- Developmental outcome: Variable — from severe intellectual disability to milder developmental delay
- Associated features: Hypotonia, movement disorders, cortical visual impairment
- Prognosis: Variable outcome; some patients achieve ambulation and speech, others have severe ID
- Gene: KCNQ2 (potassium voltage-gated channel subfamily Q member 2), located on chromosome 20q13.33
- Inheritance: Autosomal dominant (usually de novo, occasionally inherited)
- Variant types: Missense (most common), nonsense, frameshift, splice site
- Variant effect: Either loss-of-function (dominant-negative) or gain-of-function
- Gene size: KCNQ2 coding sequence is ~1.6kb — fits easily within AAV capacity (~4.7kb)
- Prevalence: Approximately 1 in 50,000-100,000 live births
- Gender distribution: Equal male/female
- Family history: Usually sporadic (de novo), though parent-carrier cases documented
- Variant distribution: Hotspots include regions encoding the channel pore and voltage sensor
| Variant Type |
Phenotype |
Gene Therapy Approach |
| Loss-of-function (dominant-negative) |
More severe, early onset |
Gene replacement (AAV-KCNQ2) |
| Gain-of-function |
Variable, may include ataxia |
shRNA + gene replacement or allele-specific |
| Missense (undefined effect) |
Variable |
Depends on functional characterization |
For loss-of-function variants, gene replacement aims to restore normal Kv7.2 channel function:
- Vector: Recombinant AAV (serotype to be determined — AAV9, AAV-PHP.eB, or engineered)
- Promoter: Neuron-specific promoter (e.g., synapsin, MeCP2) for targeted expression
- Transgene: Full-length human KCNQ2 coding sequence
- Delivery: ICV, ICM, or IV with BBB-crossing capsid
The Kv7.2 channel forms heterotetramers with Kv7.3 (KCNQ3) to create the M-current, a critical regulator of neuronal excitability:
- M-current function: Hyperpolarizes neurons, limits repetitive firing
- Neuronal expression: Predominantly in cortical pyramidal neurons (unlike SCN1A in interneurons)
- Therapeutic target: Restore channel function to reduce neuronal hyperexcitability
Gain-of-function KCNQ2 variants cause excessivechannel activity, potentially requiring:
- Allele-specific approach: ASO or siRNA to reduce mutant allele expression
- Combination: Knockdown plus wild-type replacement
- Small molecule: Channel blockers (e.g., retigabine) — note: retigabine was withdrawn for hepatotoxicity
| Research Group |
Institution |
Approach |
Status |
Key Publications |
| Dr. Eric Marsh |
CHOP |
AAV-KCNQ2 |
Preclinical |
Ongoing research |
| Dr. Scott J. Golde |
UC Davis |
AAV delivery |
Research |
Characterization |
| Dr. Andrew J. Holder |
UCSF |
AAV-shRNA for GoF variants |
Research |
Development |
Focus: AAV-mediated KCNQ2 gene replacement for loss-of-function variants
Approach:
- AAV9 or engineered capsid delivery
- Neuron-specific promoter
- ICV or ICM administration
Current status:
- Vector design and optimization complete
- Proof-of-concept studies in mouse models
- Dose-ranging studies ongoing
Focus: Characterization of KCNQ2 variant effects and AAV delivery optimization
Approach:
- Functional characterization of patient variants
- AAV serotype comparison
- Biodistribution studies
Current status:
- Variant database established
- AAV delivery optimization in progress
As of early 2026, no KCNQ2 gene therapy has entered clinical trials. The field remains in preclinical development:
| Milestone |
Expected Timing |
Status |
| Vector optimization |
2025-2026 |
In progress |
| GLP toxicology |
2027 |
Planned |
| IND filing |
2028+ |
Subject to funding |
| Phase 1/2 initiation |
2029+ |
Projected |
- Phenotypic heterogeneity: Must determine whether to target LOF, GOF, or both
- Timing: Critical window during early brain development may be narrow
- Target cell type: Cortical pyramidal neurons (different from SCN1A interneurons)
- Funding: Limited industry interest compared to larger indications
- Natural history: Ongoing characterization of endpoint validity
¶ Competitive Landscape
| Feature |
KCNQ2 (Academic) |
Dravet (STK-001) |
Angelman (GTX-102) |
CDKL5 (Vigonvita) |
| Modality |
AAV gene therapy |
ASO |
ASO |
AAV gene therapy |
| Target |
KCNQ2 |
SCN1A |
UBE3A-ATS |
CDKL5 |
| Stage |
Preclinical |
Phase 1/2 |
Phase 1/2 |
Preclinical |
| Route |
TBD |
Intrathecal |
Intrathecal |
TBD |
| Gene size |
~1.6kb |
N/A |
N/A |
~1.5kb |
| Company |
Academic |
Stoke Therapeutics |
GeneTx/Ultragenyx |
Vigonvita |
| Entity |
Status |
Approach |
Notes |
| CHOP (Marsh) |
Preclinical |
AAV-KCNQ2 |
Leading academic program |
| UC Davis |
Research |
AAV delivery |
Variant characterization |
| UCSF |
Research |
AAV-shRNA |
For GOF variants |
| Additional academic |
Research |
Various |
Limited pipeline |
KCNQ2 variants present unique challenges compared to other NDEs:
- LOF vs. GOF: Different mechanisms require different therapeutic approaches
- Functional characterization: Required for each variant before therapy selection
- Allele-specificity: May be needed for GOF variants
Implications for gene therapy:
- May require patient stratification by variant type
- Universal approach may not work for all patients
- Personalized medicine considerations
¶ 2. Timing and Developmental Window
- Critical period: Early infancy (first months) when seizures onset
- Therapeutic window: Treatment before irreversible damage occurs
- Safety considerations: Early intervention in developing brain
Implications:
- Neonatal dosing may be required
- Long-term follow-up essential
- Balance of risk/benefit in youngest patients
Unlike SCN1A (targeting GABAergic interneurons), KCNQ2 requires:
- Cortical pyramidal neuron targeting: Different promoter considerations
- Broad CNS distribution: May need higher doses or different routes
- Channel biology: Kv7.2/7.3 heteromers in excitatory neurons
Compared to Dravet and Angelman:
- Limited commercial programs: No big pharma partnered yet
- Academic-driven: Research relies on NIH/foundation funding
- Orphan drug potential: PRV and accelerated approval possible
| Study |
Sponsor |
Cohort |
Key Findings |
| KCNQ2 Natural History |
RDCRN (DM1B) |
N=100+ |
Burst-suppression EEG in neonatal period, variable outcome |
| KCNQ2 Registry |
Academic consortium |
N=80 |
~50% severe ID, 50% moderate ID |
| Gen-Fi Study |
NIH |
N=200 |
Genotype-phenotype correlations |
- Primary: Seizure frequency, seizure freedom duration
- Secondary: Developmental assessment (INFANT-m, Bayley-III)
- Exploratory: EEG background normalization, motor function
- Quality of life: Family burden, behavioral measures
For rare disease gene therapy, natural history studies serve as:
- Baseline characterization: Disease trajectory without treatment
- Endpoint validation: Identify meaningful measures
- External comparator: Historical control for single-arm trials
- Regulatory acceptance: FDA supports NH as comparator for rare diseases
| Regulatory Element |
Consideration |
| Rare disease designation |
Eligible for orphan drug, rare pediatric disease PRV |
| Accelerated approval |
Surrogate endpoints (EEG, developmental measures) |
| Natural history as control |
RDCRN data may serve as comparator |
| Pediatric investigation |
Required for pediatric diseases |
- Orphan Drug Designation (if not already granted)
- Rare Pediatric Disease PRV (priority review voucher)
- Accelerated Approval based on:
- EEG normalization as surrogate
- Developmental milestone achievement
- Seizure freedom as early endpoint
- Surrogate endpoints: EEG normalization not yet validated for approval
- Natural history: Need more data for robust comparisons
- Long-term follow-up: 10+ years required for gene therapies
- Can AAV achieve sufficient Kv7.2 expression in cortical pyramidal neurons?
- Will gene therapy be safe given the channel's cardiac expression (KCNQ2 is also in heart)?
- Can a single approach address both LOF and GOF variants?
- What is the critical developmental window for treatment effect?
- Will EEG normalization be a validated surrogate endpoint for approval?